Astellas Pharma Inc (4503.T)
2 May 2016
* Astellas names Rodrigo Fernandez executive director, international business Source text for Eikon: Further company coverage:
(Corrects minimum commitment to $200,000 from $500,000 figure given by UBS on Wednesday)
ZURICH, April 27 A $471 million UBS venture fund aims to generate annual returns "north of 10 percent" for its European and Asian investors by financing new cancer drugs, helping speed them from the lab to the point where drug companies buy their rights.
March 28 A group of lawmakers is calling on the National Institutes of Health and Department of Health and Human Services to step in and reduce the cost of Medivation Inc's and Astellas Pharma Inc's prostate cancer drug Xtandi.
* Pivotal phase III trial of Enzalutamide initiated in Metastatic Hormone Sensitive Prostate Cancer Source text for Eikon: Further company coverage:
* Decided not to refer anticipated acquisition by Leo Pharma of the portfolio of pharma dermatological products of Astellas Pharma to phase 2 investigation Source text for Eikon: Further company coverage:
Earnings vs. Estimates
Analyst Research Reports
Astellas Pharma Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.